The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive value of contrast enhancement on computed tomography for the responses to oxaliplatin-based chemotherapy with bevacizumab for hepatic metastases from colorectal cancer.
G. Osawa
No relevant relationships to disclose
K. Yoshimatsu
No relevant relationships to disclose
H. Yokomizo
No relevant relationships to disclose
T. Otani
No relevant relationships to disclose
A. Matsumoto
No relevant relationships to disclose
M. Nakayama
No relevant relationships to disclose
Y. Yano
No relevant relationships to disclose
K. Ogawa
No relevant relationships to disclose